Evidence map›Paper›PMID 25112509›Full record

ReviewNature reviews. Neurology2014

The link between multiple sclerosis and depression.

Anthony Feinstein, Sandra Magalhaes, Jean-Francois Richard, Blair Audet, Craig Moore

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 209 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03758820 nacompletednot on this mapstarted 2017, after this paper: background citation

Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)

TypeinterventionalSponsorRéseau Sep Idf OuestRan2017 to 2020Enrolled105ConditionsRelapsing Remitting Multiple Sclerosis, Fatigue, Cognitive TherapyArmsBehavorial Cognitive Therapy (BCT)
NCT05808101 terminatednot on this mapstarted 2022, after this paper: background citation

Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects

TypeobservationalSponsorWashington University School of MedicineRan2022 to 2024Enrolled51ConditionsMultiple Sclerosis, DepressionArmsNeuro-QoL T-score determination
3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Observational

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anthony FeinsteinUniversity of Toronto, 27 King's College Circle, Toronto, ON M5S 1A1, Canada.
Sandra MagalhaesNeuroepidemiology Research Unit, Research Institute of the McGill University Health Centre, Royal Victoria Hospital, 1025 Pine Avenue West, Montreal, QC H3A 1A1, Canada.
Jean-Francois RichardNeurosciences Axis, Centre Hospitalier Universitaire de Quebec Research Centre, 2705 Boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Blair AudetDepartment of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.
Craig MooreDepartment of Neurology and Neurosurgery, McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression--be it a formal diagnosis based on consensus clinical criteria, or a collection of symptoms revealed by a self-report rating scale--is common in patients with multiple sclerosis (MS) and adds substantially to the morbidity and mortality associated with this disease. This Review discusses the prevalence and epidemiology of depression in patients with MS, before covering aetiological factors, including genetics, brain pathology, immunological changes, dysregulation of the hypothalamic-pituitary-adrenal axis, and psychosocial influences. Treatment options such as antidepressant drugs, cognitive-behavioural therapy, mindfulness-based therapy, exercise and electroconvulsive therapy are also reviewed in the context of MS-related depression. Frequent comorbid conditions, namely pain, fatigue, anxiety, cognitive dysfunction and alcohol use, are also summarized. The article then explores three key challenges facing researchers and clinicians: what is the optimal way to define depression in the context of diseases such as MS, in which the psychiatric and neurological symptoms overlap; how can current knowledge about the biological and psychological underpinnings of MS-related depression be used to boost the validity of this construct; and can intervention be made more effective through use of combination therapies with additive or synergistic effects, which might exceed the modest benefits derived from their individual components?

Indexed as

Antidepressive AgentsCognitive Behavioral TherapyDepressionHumansMultiple SclerosisPrevalenceAntidepressive Agents

Identifiers

PMID25112509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.